MARKET

BIIB

BIIB

Biogen
NASDAQ

Real-time Quotes | Nasdaq Last Sale

351.96
-19.94
-5.36%
Opening 11:09 06/24 EDT
OPEN
349.48
PREV CLOSE
371.90
HIGH
358.37
LOW
347.00
VOLUME
2.56M
TURNOVER
--
52 WEEK HIGH
468.55
52 WEEK LOW
223.25
MARKET CAP
52.99B
P/E (TTM)
18.46
1D
5D
1M
3M
1Y
5Y
US STOCKS-Nasdaq, S&P 500 scale new peak as jobs recovery gains traction
reuters.com · 41m ago
Why Lilly Shares Are Moving Thursday
Eli Lilly and Company (NYSE: LLY) shares are advancing solidly Thursday following an update the company provided on its Alzheimer's program.
Benzinga · 47m ago
Alzheimer's Treatment Market Is Anticipated To Reach $2 Billion By The End Of 2027
/PRNewswire/ -- According to the Centers for Disease Control and Prevention, Alzheimer's is among the top 10 leading causes of deaths in . The death rate for the disease has increased significantly in the U.S. over the past few years. More than deaths wer...
PR Newswire - PRF · 1h ago
US STOCKS-Nasdaq set for record open as jobs recovery gains traction
reuters.com · 2h ago
Eli Lilly Jumps, Dollar Tree Slips as Stock Market Chases Infrastructure Plan Higher
marketwatch.com · 2h ago
BIIB, TALO among premarket losers
Portage Biotech PRTG -28% on stock offering.Daqo New Energy DQ -10% following a report that the U.S. is poised to bar some solar products made in China's Xinjiang region.Biogen BIIB -8% in sympathy with Lilly's Alzheimer’s therapy plan.
Seekingalpha · 2h ago
UPDATE 1-Lilly to seek accelerated FDA approval for Alzheimer's drug this year
reuters.com · 3h ago
Eli Lilly Receives FDA Breakthrough Therapy Designation for Alzheimer's Drug Candidate
MT Newswires · 5h ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of BIIB. Analyze the recent business situations of Biogen through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 33 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average BIIB stock price target is 407.86 with a high estimate of 647.00 and a low estimate of 244.00.
EPS
Institutional Holdings
Institutions: 1.53K
Institutional Holdings: 138.17M
% Owned: 91.78%
Shares Outstanding: 150.55M
TypeInstitutionsShares
Increased
346
6.43M
New
134
2.05M
Decreased
397
8.47M
Sold Out
103
1.14M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+1.03%
Pharmaceuticals & Medical Research
+1.28%
Key Executives
Chairman/Independent Director
Stelios Papadopoulos
Chief Executive Officer/Director
Michel Vounatsos
Chief Financial Officer/Executive Vice President
Michael McDonnell
Chief Human Resource Officer/Executive Vice President
Ginger Gregory
Executive Vice President/Secretary
Susan Alexander
Executive Vice President
.. ..
Executive Vice President
Alphonse Galdes
Executive Vice President
Chirfi Guindo
Executive Vice President
Alfred Sandrock
Senior Vice President/Chief Accounting Officer
Robin Kramer
Independent Director
Alexander Denner
Senior Vice President/Chief Information Officer
Mark Hernon
Independent Director
Caroline Dorsa
Independent Director
William Hawkins
Independent Director
Nancy Leaming
Independent Director
Jesus Mantas
Independent Director
Richard Mulligan
Independent Director
Brian Posner
Independent Director
Eric Rowinsky
Independent Director
Stephen Sherwin
No Data
About BIIB
Biogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA). It also has a collaboration agreement with Genentech, Inc. (Genentech), a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA indicated for the treatment of CLL and follicular lymphoma, and other anti-CD20 therapies. The Company's product candidate includes OCREVUS; Biosimilar adalimumab; Aducanumab; E2609; BIIB074; BAN2401; Opicinumab; CIRARA; BIIB061; BIIB054; BIIB067, and BIIB068.

Webull offers kinds of Biogen Inc stock information, including NASDAQ:BIIB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BIIB stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BIIB stock methods without spending real money on the virtual paper trading platform.